Filing Flows › Zevra Therapeutics (ZVRA) › R&D spending
Zevra Therapeutics (ZVRA) R&D spending by quarter
Zevra Therapeutics' R&D spending was $4.9M in Q3 2026 (third quarter 2026), +10% from Q2 2026. Over the last 6 quarters it ranged from $2.6M (Q4 2025) to $4.9M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $4.9M | +10% | +44% |
| Q2 2026 | $4.5M | +71% | +31% |
| Q4 2025 | $2.6M | -24% | — |
| Q3 2025 | $3.4M | 0% | — |
| Q2 2025 | $3.4M | +5% | — |
| Q1 2025 | $3.3M | — | — |
Q3 2026 at a glance
Zevra Therapeutics, Q3 2026: revenue $37.8M (+45% year over year), operating margin 30.7%, net earnings $19.2M, operating cash flow $10.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Zevra Therapeutics' R&D spending?
Zevra Therapeutics' R&D spending was $4.9M in Q3 2026 (third quarter 2026), +10% from Q2 2026.
How has Zevra Therapeutics' R&D spending changed?
Over the last 6 quarters it ranged from $2.6M (Q4 2025) to $4.9M (Q3 2026).